IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4505
Positioning
Market Dominance
Manufacturing
Medical Equipment
$211M
Nadim Yared
CVRx, Inc. focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe and internationally.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$CVRX CVRx, Inc. | 30 | 38 | 31 | 16 | - | - | -138.5% | -52.0% | 84.4% | -98.9% | -101.4% | 24.4% | 0.0% | 166.0x | $211M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CVRx, Inc. (CVRX) receives a "Avoid" rating with a composite score of 30.3/100. It ranks #4505 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Nadim Yared
Chief Executive Officer
Labor Force
160
38
27
25
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CVRX
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CVRX.
View All RatingsImproving capital utilization rates confirmed
ROE proxy -138.5% (sector -2.5%)
GM 84% vs sector 43%, OM -99% vs sector 1%
Capital turnover N/A, R&D intensity 19.7%
Rev growth 24%, 5yr history
Interest coverage -34.6x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags CVRx, Inc. with an Avoid rating, assigning a composite score of 30.3/100 and 1 out of 5 stars. Ranked #4505 of 7,333 stocks, CVRX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CVRX's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -138.5% (sector avg: -2.5%), gross margins of 84.4% (sector avg: 42.5%), net margins of -101.4% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 31/100, CVRX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 4.09x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
CVRx, Inc.'s investment score of 27/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 24.4% vs. a sector average of 5.9% and a return on assets of -52.0% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CVRx, Inc. is experiencing notably weak momentum with a score of just 16/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 24.4% year-over-year, while a beta of 1.77 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
CVRX's stability score of 25/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.77 and a debt-to-equity ratio of 166.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
CVRx, Inc.'s short interest score of 35/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.77), elevated leverage (D/E: 166.00x), micro-cap liquidity risk. At $211M (micro-cap), CVRX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
CVRx, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4505 of 7,333 overall (39th percentile). Key comparisons include ROE of -138.5% trailing the -2.5% sector median and operating margins of -98.9% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CVRX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (16) would have the largest impact on the composite score.
ROE 5485% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 99% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 7763% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate CVRx, Inc. (CVRX) as Avoid with a composite score of 30.3/100 at a current price of $7.22. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in quality (38th percentile) and value (31th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (16th percentile) and stability (25th percentile) tempers our overall conviction. We assign a No Moat rating (39/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
CVRx, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.3/100 places it at rank #4505 in our full 7,333-stock universe. At $211M in market capitalization, CVRx, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 24%, though momentum at the 16th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 84% (+41.9pp vs sector) narrow to operating margins of -99% (-100.1pp vs sector) and net margins of -101.4%, yielding a gross-to-net conversion rate of -120%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $7.22, CVRx, Inc. is trading at a premium to fundamental value. Our value factor score of 31/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 4.1x, P/S of 3.0x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 84% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 24% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Avoid rating (composite 30.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (166% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Thin net margins of -101.4% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Very High uncertainty rating to CVRx, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.77), significant leverage (166% debt-to-equity), current negative profitability (net margin -101.4%). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.77); significant leverage (166% debt-to-equity); current negative profitability (net margin -101.4%); below-average price stability (25th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 25th percentile and quality factor at the 38th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 84% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate CVRx, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-138.5%), elevated leverage (166% D/E), negative profitability, weak asset returns (ROA -52.0%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — CVRx, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, CVRx, Inc. receives a Avoid rating with a composite score of 30.3/100 (rank #4505 of 7,333). Our quantitative framework assigns a No Moat (39/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 27/100.
Our analysis does not support a constructive view on CVRx, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign CVRx, Inc. a meaningful economic moat, scoring 39/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 12.9/20.
The strongest moat sources are growth durability (12.9/20) and margin superiority (12.8/20). Rev growth 24%, 5yr history. GM 84% vs sector 43%, OM -99% vs sector 1%. These pillars form the core of CVRx, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and financial resilience (3.7/20). ROE proxy -138.5% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect CVRx, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 84% providing a solid profitability foundation, robust top-line growth of 24% expanding the revenue base. The margin cascade from 84% gross to -99% operating to -101.4% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 38th percentile.
The margin profile shows gross margins of 84%, operating margins of -99%, net margins of -101.4%. Return metrics include ROE of -138.5% and ROA of -52.0%. Relative to the Manufacturing sector, gross margins are 41.9 percentage points above the sector median of 43%, and ROE of -138.5% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 166%, which may limit financial flexibility, revenue growth of 24%. The sector median D/E is 0%, putting CVRx, Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Weak momentum (16th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
High beta of 1.77 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
CVRx Inc (CVRX) reports increased revenue and expanded sales territories, while navigating financial hurdles and strategic transitions.
There's been a major selloff in CVRx, Inc. ( NASDAQ:CVRX ) shares in the week since it released its full-year report...
CVRx (CVRX) Q4 2025 earnings call recap: revenue growth, 2026 guidance, Category 1 CPT impact, and BENEFIT-HF trial upside—read key takeaways.
Operator: Greetings, and welcome to the CVRx, Inc. Q4 2025 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Above 50MA
37.18%
Net New Highs
+51081